These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38011786)

  • 21. Upregulation of ADAM12 Is Associated With a Poor Survival and Immune Cell Infiltration in Colon Adenocarcinoma.
    Huang Z; Lai H; Liao J; Cai J; Li B; Meng L; Wang W; Mo X; Qin H
    Front Oncol; 2021; 11():729230. PubMed ID: 34604068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-associated fibroblasts derived extracellular vesicles promote angiogenesis of colorectal adenocarcinoma cells through miR-135b-5p/FOXO1 axis.
    Dai X; Xie Y; Dong M
    Cancer Biol Ther; 2022 Dec; 23(1):76-88. PubMed ID: 35100092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TIMP2 is associated with prognosis and immune infiltrates of gastric and colon cancer.
    Jian F; Yanhong J; Limeng W; Guoping N; Yiqing T; Hao L; Zhaoji P
    Int Immunopharmacol; 2022 Sep; 110():109008. PubMed ID: 35792273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MCM5 is an oncogene of colon adenocarcinoma and promotes progression through cell cycle control.
    Mao J; Shen J; Lu X; Cai Y; Tao R; Deng Y; Zhang Y; Wu Y; Chen W
    Acta Histochem; 2023 Aug; 125(6):152072. PubMed ID: 37385108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-152-3p facilitates cell adhesion and hepatic metastases in colorectal cancer via targeting AQP11.
    Zhu X; Jin X; Li Z; Chen X; Zhao J
    Pathol Res Pract; 2023 Apr; 244():154389. PubMed ID: 36889174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
    Chi PD; Li L; Fan YY; Wu CY
    Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of ANXA1 as a potential prognostic biomarker and correlating with immune infiltrates in colorectal cancer.
    Liang Z; Li X
    Autoimmunity; 2021 Mar; 54(2):76-87. PubMed ID: 33596760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitor of growth 4 suppresses colorectal cancer growth and invasion by inducing G1 arrest, inhibiting tumor angiogenesis and reversing epithelial-mesenchymal transition.
    Qu H; Yin H; Yan S; Tao M; Xie Y; Chen W
    Oncol Rep; 2016 May; 35(5):2927-35. PubMed ID: 26936485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
    Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
    Front Immunol; 2019; 10():6. PubMed ID: 30761122
    [No Abstract]   [Full Text] [Related]  

  • 30. Comprehensive analysis of the immune implication of FABP4 in colon adenocarcinoma.
    Wu D; Xiang L; Peng L; Gu H; Tang Y; Luo H; Liu H; Wang Y
    PLoS One; 2022; 17(10):e0276430. PubMed ID: 36264920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SOCS3 methylation in synergy with Reg3A overexpression promotes cell growth in pancreatic cancer.
    Wang J; Zhou H; Han Y; Liu X; Wang M; Wang X; Yin G; Li X; Xiang M
    J Mol Med (Berl); 2014 Dec; 92(12):1257-69. PubMed ID: 24996521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway.
    Ren S; Xing Y; Wang C; Jiang F; Liu G; Li Z; Jiang T; Zhu Y; Piao D
    Int J Biochem Cell Biol; 2020 Aug; 125():105777. PubMed ID: 32504672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the PI3K/Akt signaling pathway.
    Jiang L; Liu Y; Liu M; Zheng Y; Chen L; Shan F; Ji J; Cao Y; Kai H; Kang X
    Environ Toxicol; 2024 Jan; 39(1):85-96. PubMed ID: 37665173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of SMC1A on immune microenvironment and cancer stem cells in colon adenocarcinoma.
    Li J; Zhou Q; Liu L; He J
    Cancer Med; 2023 Jun; 12(11):12881-12895. PubMed ID: 37096492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential roles of highly expressed PFKFB4 in colon adenocarcinoma patients.
    Gu X; Dai X; Huang Y; Zhang Y; Dong L; Gao C; Wang F
    Sci Rep; 2023 Sep; 13(1):16284. PubMed ID: 37770581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling.
    Zhong Q; Fang Y; Lai Q; Wang S; He C; Li A; Liu S; Yan Q
    J Exp Clin Cancer Res; 2020 Jul; 39(1):132. PubMed ID: 32653013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ETV4 transcriptionally activates HES1 and promotes Stat3 phosphorylation to promote malignant behaviors of colon adenocarcinoma.
    Yao D; Bao Z; Qian X; Yang Y; Mao Z
    Cell Biol Int; 2021 Oct; 45(10):2129-2139. PubMed ID: 34270850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.
    Hock H; Dorsch M; Kunzendorf U; Qin Z; Diamantstein T; Blankenstein T
    Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2774-8. PubMed ID: 8464888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-448 targets IDO1 and regulates CD8
    Lou Q; Liu R; Yang X; Li W; Huang L; Wei L; Tan H; Xiang N; Chan K; Chen J; Liu H
    J Immunother Cancer; 2019 Aug; 7(1):210. PubMed ID: 31391111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-36α inhibits colorectal cancer metastasis by enhancing the infiltration and activity of CD8
    Wei X; Yao Y; Wang X; Sun J; Zhao W; Qiu L; Zhai W; Qi Y; Gao Y; Wu Y
    Int Immunopharmacol; 2021 Nov; 100():108152. PubMed ID: 34555640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.